Everest Group enters Q2 earnings season with the Street turning more constructive, yet the stock still trades below most bullish targets — a gap that has narrowed sharply over a month of strong price action.
The analyst activity this week tells a clear directional story. Barclays lifted its target from $380 to $420, maintaining an Overweight rating — the most aggressive move of the bunch. Keefe, Bruyette & Woods raised to $414 from $411, holding its Outperform. Morgan Stanley nudged its Equal-Weight target to $360 from $355, staying cautious. The pattern is consistent: bulls are chasing higher, but the sideline voices aren't moving. The consensus mean target now sits at $391, just above the current price of $373, implying modest upside from here. That gap would have looked far more attractive a month ago — EG has gained 11.6% in 30 days, compressing the margin of safety for late buyers.
Positioning in the lending market offers little drama, which is its own signal. Borrow availability is exceptionally loose, running at over 3,374% of short interest — meaning there are roughly 34 shares available for every one currently lent out. Cost to borrow is a negligible 0.53%, barely moved on the week. Short interest itself is 3.6% of free float, down about 3.4% over the past week. That said, the 30-day picture is more nuanced: SI has risen 25% versus mid-June levels, suggesting some tactical shorts built positions during the stock's earlier weakness. Those shorts have been squeezed by the recent rally, not by a borrow-market tightening. Options positioning reflects the same mild defensiveness: the put/call ratio at 1.34 is only fractionally above its 20-day average, and the z-score of 0.18 is well within normal range. No particular hedging urgency here.
Valuation tells an interesting story for a reinsurer. The price-to-book ratio is 0.81 — below book value — having risen roughly 7 basis points over the past month alongside the price recovery. The earnings yield ranks respectably in the sector, and EV/EBITDA at 7.0x is undemanding. The ORTEX short score of 41.4 has been drifting lower over the past two weeks, consistent with short sellers reducing exposure as price momentum improved. Factor scores put EPS surprise at the 79th percentile, reflecting a company that has consistently beaten estimates, while the short score rank at the 26th percentile confirms this is not a heavily pressed name. Peers ACGL and AXS each gained roughly 4.9% and 5.2% respectively on the week — marginally outpacing EG's 4.5% — while RNR barely moved at 0.2%, suggesting EG tracked the broader P&C insurance rally without standing out on either side.
The earnings history adds modest comfort for holders going into the July 29 print. Q1 results in late April produced a one-day move of about +2.8% and a five-day move of roughly +2.2% — gentle, positive reactions that suggest the market wasn't braced for anything dramatic either way. The bull case rests on improving core loss ratios and reinsurance pricing tailwinds. The bear case centres on social inflation eating into casualty reserves and catastrophe exposure — risks that have kept multiple well-regarded firms at neutral-equivalent ratings despite the recent target hikes.
With three analysts raising targets in the span of two days and Q2 results three weeks away, the key question heading into July 29 is whether Everest's loss ratio trajectory has continued to improve — or whether cat losses from the first half of 2026 complicate the picture.
See the live data behind this article on ORTEX.
Open EG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
